Selventa

Cambridge, MA

Selventa (formerly known as Genstruct) is focused on the application of computational systems biology to drug discovery and development. The company is developing disease-specific mechanistic models that are used to discover the mechanisms underlying disease, drug action, and drug efficacy. Pappas Ventures originally invested in Incellico, which was acquired by Genstruct in July 2003.